Post-Trial Obligations & Continued Access

The obligations and arrangements — often underspecified — governing what happens to participants after a study ends: whether they keep a device that is benefiting them, who maintains and supports it, and who bears the cost, versus explanting it or simply withdrawing support. Sponsors, companies, and academic labs may fold, lose funding, or discontinue a product line, stranding participants who came to depend on restored communication or control.

This is a recognized ethical fault line in neurotechnology research: participants accept surgical risk to advance a field, yet post-trial responsibilities are frequently left vague. Emerging norms call for planning continued access, maintenance, and orderly wind-down — including explant options and long-term follow-up — before enrollment, and for treating device abandonment as a foreseeable harm to be mitigated rather than an unfortunate accident.